Biotech

Affibody gets izokibep ‘back on track’ after Acelyrin rejection

Affibody may not have expected to be working on izokibep again, but the Swedish biotech hasn’t wasted an opportunity to showcase the drug’s potential.

James Waldron Jun 5, 2026 10:42am

Fierce Biotech Layoff Tracker 2026: Fulcrum, Novartis & more

Jun 5, 2026 9:45am

Entry Japan with Clarity Execute with Confidence

PATH-Solution

Brought to you by Alfresa Holdings Corporation

Illustration for Fierces Chutes Ladders feature showing a blue city skyline with executives making career moves o

AstraZeneca adds FDA cell and gene veteran—Chutes & Ladders

Jun 5, 2026 8:30am

Carl Sailer on AI, market trends, and strategic planning in biotech

Brought to you by Syneos Health

How RA Capital is offering ‘Chinese clinical expertise in a box’

Jun 5, 2026 8:19am